-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, P37/nNtvnwL/ZFLy69O+UUNyj2BMZUzxsgXfd96nj8Ux/NDtaQo4qKMW4NxSXrrD MOIJdhu8n+wMTny2EbJebw== 0001036050-99-000214.txt : 19990211 0001036050-99-000214.hdr.sgml : 19990211 ACCESSION NUMBER: 0001036050-99-000214 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19990205 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19990210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE CENTRAL INDEX KEY: 0000094784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870277826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-06533 FILM NUMBER: 99527346 BUSINESS ADDRESS: STREET 1: 31 NEWBURY ST STREET 2: SUITE 300 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6174250200 MAIL ADDRESS: STREET 1: 31 NEWBURY STREET STREET 2: SUITE 300 CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE DATE OF NAME CHANGE: 19790521 8-K 1 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) February 5, 1999 ---------------- BOSTON LIFE SCIENCES, INC. -------------------------- (Exact name of registrant as specified in its charter)
Delaware 0-6533 87-0277826 - -------------------------------- ------ ---------------------------- (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File No.) Identification No.) 31 Newbury Street, Suite 300 Boston, Massachusetts 02116 - ------------------------------------------ --------------- (Address of principal executive offices) Zip Code
Registrant's telephone number, including area code (617) 425-0200 -------------- Item 5. Other Events. ------------- On February 5, 1999 the Company announced the identification and production of another apparently highly potent, novel anti-angiogenic molecule in the course of its ongoing research in the area of anti-angiogenesis. The molecule was found using the same in vitro screening assay and techniques that were used to successfully identify Troponin, the Company's lead anti-angiogenic agent. The Company stated that the molecule appears to demonstrate in vitro anti-angiogenic potency that surpasses other compounds, including Troponin. The Company cautioned that more work needs to be done to clarify the role of this new molecule in BLSI's anti-angiogenic product lineup. Item 7. Exhibits. -------- The following Exhibits are filed as part of this report on Form 8-K: 99.1 Press Release, dated February 5, 1999. 1 SIGNATURES - ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto authorized. BOSTON LIFE SCIENCES, INC. Dated: February 8, 1999 By: /s/Joseph Hernon ---------------- Joseph Hernon Chief Financial Officer 2 BOSTON LIFE SCIENCES, INC. CURRENT REPORT ON FORM 8-K EXHIBIT INDEX Exhibit No. Page(s) - ----------- ------- 99.1 Press Release, dated February 5, 1999 4 3 EX-99.1 2 PRESS RELEASE DATED FEBRUARY 5, 1999 Exhibit 99.1 FOR IMMEDIATE RELEASE --------------------- BOSTON LIFE SCIENCES ANNOUNCES DEVELOPMENT PROGRAM IN A SECOND POTENT ANTI-ANGIOGENIC MOLECULE Boston, MA--February 5, 1999--Boston Life Sciences, Inc. (NASDAQ: BLSI) announced today that in the course of the Company's ongoing research in anti- angiogenesis, it has identified and produced another apparently highly potent, novel anti-angiogenic molecule. The Company's lead anti-angiogenic agent, Troponin, a naturally-occurring protein, is in late stage preclinical development for the potential treatment of solid tumor metastases and eye diseases. Using the same in vitro screening assay and techniques that were used to successfully identify Troponin, the Company found a molecule that appears to demonstrate in vitro anti-angiogenic potency that surpasses other compounds, including Troponin. "Our in vitro screening techniques test the ability of candidate compounds to inhibit growth factor stimulation of endothelial cell growth. To the best of our knowledge, Troponin has been the most potent naturally-occurring anti- angiogenic protein demonstrated in this assay. We are therefore extremely excited that this molecule appears to have greater activity in this assay than even Troponin," stated Dr. Marc Lanser, Chief Scientific Officer of BLSI. "Since our own repeated experience thus far in animal trials indicates that such in vitro potency is a good predictor of in vivo anti-tumor activity, we are optimistic that this new molecule may have great potential as an additional anti-angiogenic product in our portfolio of products. The benefit of significantly increased potency could ultimately translate into very important practical advantages in dosage and ease of administration, if successfully brought into human use. Naturally, since these are early results, more work needs to be done to clarify the role of this new molecule in BLSI's anti- angiogenic product lineup," added Dr. Lanser. BLSI is developing novel treatments for cancer, autoimmune disease, and central nervous system disorders. In addition to Troponin I, products awaiting FDA review, in clinical trials or in preclinical development by BLSI include THERAFECTIN for the treatment of Rheumatoid Arthritis; AF1 for the potential treatment of stroke and spinal cord injury; Altropane, a radioimaging agent for the diagnosis of Parkinson's Disease; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. The foregoing contains forward-looking statements with regard to product development expectations, timelines, and regulatory filings, which may not be realized due to the uncertainties inherent in the research and development process. For further information please contact: Marc E. Lanser, MD Chief Scientific Officer 617-425-0200 4 -----END PRIVACY-ENHANCED MESSAGE-----